ABT-199 (Venetoclax): Potent Selective Bcl-2 Inhibitor for Hematologic Malignancies

Executive Summary: ABT-199 (Venetoclax) is a highly selective Bcl-2 inhibitor with sub-nanomolar affinity (Ki < 0.01 nM) and over 4800-fold selectivity compared to Bcl-XL and Bcl-w, showing negligible Mcl-1 inhibition (Shang et al., 2020). It promotes apoptosis via mitochondrial pathway activation, selectively targeting Bcl-2-dependent cancer cells, notably in non-Hodgkin lymphoma (NHL) and acute myelogenous leukemia (AML) models (APExBIO, A8194). Its solubility profile (≥43.42 mg/mL in DMSO) and oral bioavailability facilitate in vitro and in vivo research. ABT-199 minimizes Bcl-XL-associated toxicity, sparing platelets while enabling robust apoptosis assays. The compound is widely used in preclinical and translational studies, underpinning therapeutic strategies for hematologic malignancies (DOI).

Biological Rationale

The evasion of apoptosis is a hallmark of cancer, particularly in hematologic malignancies such as NHL and AML (Shang et al., 2020). The Bcl-2 family of proteins regulates the mitochondrial pathway of apoptosis, with anti-apoptotic members like Bcl-2, Bcl-XL, and Mcl-1 opposing cell death (DOI). Overexpression of Bcl-2 is implicated in resistance to chemotherapeutic agents and is a diagnostic marker in follicular lymphoma (DOI). Selective inhibition of Bcl-2 restores apoptotic sensitivity in cancer cells reliant on this survival pathway.

Mechanism of Action of ABT-199 (Venetoclax), Bcl-2 inhibitor, potent and selective

ABT-199 (Venetoclax) is a BH3-mimetic that binds selectively to the hydrophobic groove of Bcl-2, inhibiting its anti-apoptotic function (Shang et al., 2020). This displacement frees pro-apoptotic proteins BAX and BAK, triggering mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and downstream caspase activation (DOI). ABT-199 exhibits negligible activity against Bcl-XL and Mcl-1, minimizing off-target cytotoxicity, especially to platelets (APExBIO). The mitochondrial pathway specificity distinguishes ABT-199 from earlier, less selective Bcl-2/Bcl-XL inhibitors.

Evidence & Benchmarks

• ABT-199 exhibits sub-nanomolar binding affinity (Ki < 0.01 nM) for Bcl-2, with >4800-fold selectivity over Bcl-XL and Bcl-w, and no measurable inhibition of Mcl-1 (Shang et al., 2020, Table 1).
• In vitro, ABT-199 induces apoptosis in Bcl-2-dependent NHL and AML cell lines at 4 μM for 24 h, with minimal impact on non-target cells (DOI, Methods).
• In vivo, oral administration at 100 mg/kg in Eμ-Myc mouse models results in significant tumor regression without platelet toxicity (Shang et al., 2020, Figure 4).
• Combined Bcl-2 inhibition with ABT-199 and Mcl-1 targeting synergistically reduces viability in resistant glioblastoma models (Shang et al., 2020, Results).
• ABT-199 is orally bioavailable, stable at -20°C in DMSO, and dissolves at ≥43.42 mg/mL in DMSO, supporting reproducible research workflows (APExBIO).

For further mechanistic clarification and advanced application scenarios, this article extends 'ABT-199 (Venetoclax): Precision Tool for Targeting Bcl-2' by detailing selectivity benchmarks and translational metrics. For actionable protocols and troubleshooting, see 'ABT-199 Venetoclax: Precision Bcl-2 Inhibitor for Hematol...'; this article updates efficacy metrics and workflow integration for newer research models.

Applications, Limits & Misconceptions

ABT-199 (Venetoclax) is validated for:

• Delineating the Bcl-2 mediated cell survival pathway in hematologic malignancies (APExBIO).
• Apoptosis assays and mitochondrial pathway studies in NHL and AML models.
• Screening for resistance mechanisms, especially Mcl-1 dependence (Shang et al., 2020).
• Preclinical evaluation of combined Bcl-2 and Mcl-1 inhibition strategies.
• Protocol optimization for minimizing Bcl-XL-mediated platelet toxicity (DOI).

Its use is limited in tumors with high Mcl-1 expression or those lacking Bcl-2 dependence. For context, 'Leveraging ABT-199 (Venetoclax), Bcl-2 Inhibitor, Potent ...' offers troubleshooting for apoptosis and cytotoxicity assays. Here, we provide updated selectivity and resistance clarifications.

Common Pitfalls or Misconceptions

• ABT-199 is not effective in Mcl-1-dependent tumors: High Mcl-1 expression confers resistance (see Shang et al., 2020).
• It does NOT inhibit Bcl-XL at relevant concentrations: Minimal platelet toxicity is a key advantage but limits efficacy in Bcl-XL-driven cancers.
• Solubility in ethanol or water is poor: Only use DMSO for stock solutions as per product page.
• Not recommended for long-term solution storage: Prepare fresh solutions for each experiment.
• Not a pan-Bcl-2 family inhibitor: Selectively targets Bcl-2, not Mcl-1 or Bcl-XL.

Workflow Integration & Parameters

For in vitro studies, ABT-199 is typically used at 4 μM for 24 hours. For in vivo models such as Eμ-Myc mice, the standard oral dosage is 100 mg/kg (Shang et al., 2020). Prepare stock solutions in DMSO at concentrations ≥43.42 mg/mL. Store stocks at -20°C; avoid long-term storage in solution (APExBIO). Use appropriate controls, as platelets are spared due to lack of Bcl-XL inhibition. For apoptosis or cytotoxicity assays, combine with Mcl-1 inhibitors when resistance is encountered. See 'ABT-199 (Venetoclax): Selective Bcl-2 Inhibition in Apopt...' for advanced nuclear-mitochondrial pathway workflows; this article updates with new selectivity and solubility guidance.

Conclusion & Outlook

ABT-199 (Venetoclax) from APExBIO (SKU A8194) is a benchmark compound for selective Bcl-2 inhibition in apoptosis research. Its potency and selectivity underpin its widespread adoption in hematologic malignancy models, enabling reproducible and mechanistically precise investigations. While resistance in Mcl-1-dependent tumors remains a limitation, combinatorial strategies are under active investigation. Ongoing refinements in protocol integration and selectivity assessment will further expand its utility in cancer research and translational applications (Shang et al., 2020).

For detailed product specifications and ordering, visit the ABT-199 (Venetoclax), Bcl-2 inhibitor, potent and selective product page.